A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).

Sponsor
Novo Nordisk A/S
Study ID
NCT07081178
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    Semaglutide injection will be self-administered once weekly subcutaneously at any time of the day with or without meals.

Study Details

Participants will be treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician for the management of obesity. The purpose of this study is to collect data on the effect of Semaglutide under everyday conditions in participants. Participants and doctor had already decided that they will get semaglutide prescribed by doctor, independently of patient's participation in this study. The study will last for 12 months.

Key Dates

Start date
Aug 8, 2025
Status verified
Apr 2026
Primary completion
Dec 18, 2025
Completion
Dec 18, 2025

Study Design

Enrollment
100 participants (actual)

Arms

  • Arm: Group A
    Participants will be treated with commercially available semaglutide along with lifestyle modification in the routine clinical practice.
  • Arm: Group B
    Participants with lifestyle modification in the routine clinical practice will be included.

Primary Outcome Measure

Change in relative body weight [ Time Frame: From baseline to month 6 and month 9 ]

Related Studies